New hope for teens with chronic Graft-Versus-Host disease: belumosudil under study
NCT ID NCT06616415
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug belumosudil in Chinese teenagers aged 12 to 18 with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. The goal was to see how well the drug works and how safe it is for those who didn't respond to steroids. Six participants took a tablet once daily, and researchers measured drug levels, response rates, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belumosudil (a drug taken as a tablet to treat chronic graft-versus-host disease)
What this could lead to
If it works, this could offer a new treatment option for teenagers with chronic graft-versus-host disease who haven't improved with steroids.
What could go wrong
This is a very small study (only 6 participants) and is already completed, so results may not apply to all patients. The drug may not work better than existing treatments or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 1560001
Beijing, 100045, China
-
Investigational Site Number : 1560002
Shanghai, 200127, China